Vancouver, BC–(Business Wire)– biOasis Technologies Inc. (TSX.V:BTI) announces its board of directors elected by the shareholders at its recently held Annual General Meeting held July 26, 2011:
Robin Hutchison* Chairman of the Board David Clark CA
Terry Pearson Ph.D.
Chris Fibiger PH.D.
Michael Hutchison Q.C.
Chairman of the Audit Committee
Member of the Audit Committee
Member of the Compensation, Governance and Nominating Committee
Mr Ron Erickson is a new board appointment and brings over 30 years experience as an attorney and senior level executive and who is currently Chairman and Chief Executive Officer (“CEO”) of Visualant Inc. a company developing low-cost, high speed, light- based security and quality control solutions for use in homeland security, anti- counterfeiting, forgery/fraud prevention, brand protection and process control applications.
The Board also appointed the following officers of the Company:
Robin Hutchison, President and CEO
David Clark, Chief Financial Officer and Corporate Secretary
biOasis Technologies Inc. is a biopharmaceutical company engaged in the development and commercialization of products for the diagnosis and treatment of neurological diseases and disorders. Its products and technologies are intended for use within the healthcare and life science research markets. The Company is currently developing Cognitest™, a blood test for the diagnosis of Alzheimer’s disease. biOasis is also developing Transcend, a proprietary molecular carrier intended to transport drugs across the Blood-Brain Barrier for treatment of a wide range of neurological, oncological and infectious disease applications.
“Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release”
On Behalf of the Board of Directors
Chairman & CEO